Deleted Tweets From Scott Gottlieb, R-D.C.

RT @US_FDA: FDA, @CDCgov, & partners are investigating a new multistate outbreak of E. coli likely linked to romaine lettuce. Consumers nationwide shouldn’t eat & should discard romaine lettuce.

#FDA's update to its device safety plan. More major announcements next week on how we'll modernize our 510K process. We set a key new goal re: device safety: ensuring U.S. is consistently 1st in world to act on device safety signals to protect patients. https://t.co/9AurKaim6v https://t.co/1NKDopAXP0

RT @SGottliebFDA: #FDA appreciates the voluntary efforts by any growers, distributors to withdraw romaine supply from the market and urges consumers to heed advice to discard products. We will work hard to pro

We're tracing back romaine lettuce to the source of contamination. As we learn more we can narrow our advice. https://t.co/fGAWERv9K1 We know the pathogen isn't related to the Yuma linked romaine outbreak from spring. We'll provide consumers with additional information today. https://t.co/ofRT0k6MB9

FDA will soon release guidance to make it easier to get a cancer companion diagnostic approved for use with an class of drugs to give providers more prescribing flexibility and to reduce likelihood of patients undergoing multiple biopsies to target drugs https://t.co/RGkBar7FeQ https://t.co/wJLcpwNYHd

We announced that after #FDA reached out to seven manufacturers marketing certain devices to women for unapproved or uncleared uses, all changed their websites to remove claims associated with “vaginal rejuvenation” and other unapproved treatments. https://t.co/CfYeDwlucG

#FDA will hold a public ad-com meeting on February 12 to discuss the safety and effectiveness of surgical mesh intended for transvaginal pelvic organ prolapse repair. We're seeking expert opinion on whether we should consider additional regulatory actions. https://t.co/Nq7vLUpKFs

RT @SGottliebFDA: #FDA will continue to provide daily updates in current outbreak related to romaine lettuce and additional advice to consumers. We recognize the challenges and hardships this outbreak imposes

We've created an #FDA resource for patients and healthcare providers who may have questions regarding the recent impurities found in certain valsartan, irbesartan and losartan products, also known as ARBs. More information on ARBs can be found here: https://t.co/EXl8c3HEIU

#FDA is committed to making sure patients and healthcare providers have access to the latest information on the valsartan drug recalls. We’ll continue to post regular updates on the investigation to keep the public informed about affected products: https://t.co/HZb3YT0060

Patients who have received drug products produced by Pharm D and have concerns should contact their health care professional. #FDA will continue to work to mitigate risk and assure the safety of compounded drug produced by outsourcing facilities.

RT @FDA_Drug_Info: Join FDA for a public meeting Nov 27 to provide input on the underlying causes of #drugshortages & make recommendations for actions to prevent or reduce drug shortages. https://t.co/jCNYI

Now Showing: When Good Thanksgiving Leftovers Go Bad! Don’t want a starring role in this production? Check out this chart to find out how long every type of food stays good in the fridge or freezer. https://t.co/bkL7j25qmA https://t.co/ESFtU8cUSM

ALERT: Patients and healthcare professionals should check their medical supplies for compounded sterile drug products from Pharm D Solutions due to lack of sterility assurance. These products could put patients at risk. https://t.co/RpjCiZsC3u

Setting out a buffet for Thanksgiving? Check out how to serve it up safe: https://t.co/TTMjXHv0Op https://t.co/MlIucGRMyA

New efforts to strengthen device safety registry networks containing patient data will help us answer crucial questions especially for devices affecting women’s health to better treat fibroids, pelvic floor disorders and other conditions. https://t.co/9AurKaim6v https://t.co/rt0NFxRR2e

NEW REPORT: Strong actions taken by @FDADeviceInfo to increase inspections of foreign medical device firms by 243% over past decade; increased oversight led to improved compliance, improved device quality; more details in newly issued enforcement report https://t.co/3oWAUrvygW https://t.co/Sio0vPR1ex

RT @FDASpox: FDA is alerting patients and health care professionals to a voluntary recall of certain lots of valsartan-containing products from Mylan, due to an NDEA impurity. See the list of valsartan pr

RT @FDAOncology: New to cancer patient advocacy wondering how FDA works? Join us Tuesday, Nov 27, for #FDAOncology's 2nd annual workshop, Partners in Progress #OCEPIP18 in person at FDA or online: https://t.c

#FDA employs targeted, risk-based approach to address specific device concerns. We sent six warning letters to makers of automated external defibrillators and worked w/firms to address problems; now 70% drop in annual recalls and 27% drop in adverse events https://t.co/3oWAUrvygW https://t.co/4yeARQIz1h

RT @US_FDA: FDA, @CDCgov, & partners are investigating a new multistate outbreak of E. coli likely linked to romaine lettuce. Consumers nationwide shouldn’t eat & should discard romaine lettuce.

#FDA's update to its device safety plan. More major announcements next week on how we'll modernize our 510K process. We set a key new goal re: device safety: ensuring U.S. is consistently 1st in world to act on device safety signals to protect patients. https://t.co/9AurKaim6v https://t.co/1NKDopAXP0

RT @SGottliebFDA: #FDA appreciates the voluntary efforts by any growers, distributors to withdraw romaine supply from the market and urges consumers to heed advice to discard products. We will work hard to pro

We're tracing back romaine lettuce to the source of contamination. As we learn more we can narrow our advice. https://t.co/fGAWERv9K1 We know the pathogen isn't related to the Yuma linked romaine outbreak from spring. We'll provide consumers with additional information today. https://t.co/ofRT0k6MB9

FDA will soon release guidance to make it easier to get a cancer companion diagnostic approved for use with an class of drugs to give providers more prescribing flexibility and to reduce likelihood of patients undergoing multiple biopsies to target drugs https://t.co/RGkBar7FeQ https://t.co/wJLcpwNYHd

We announced that after #FDA reached out to seven manufacturers marketing certain devices to women for unapproved or uncleared uses, all changed their websites to remove claims associated with “vaginal rejuvenation” and other unapproved treatments. https://t.co/CfYeDwlucG

#FDA will hold a public ad-com meeting on February 12 to discuss the safety and effectiveness of surgical mesh intended for transvaginal pelvic organ prolapse repair. We're seeking expert opinion on whether we should consider additional regulatory actions. https://t.co/Nq7vLUpKFs

RT @SGottliebFDA: #FDA will continue to provide daily updates in current outbreak related to romaine lettuce and additional advice to consumers. We recognize the challenges and hardships this outbreak imposes

We've created an #FDA resource for patients and healthcare providers who may have questions regarding the recent impurities found in certain valsartan, irbesartan and losartan products, also known as ARBs. More information on ARBs can be found here: https://t.co/EXl8c3HEIU

#FDA is committed to making sure patients and healthcare providers have access to the latest information on the valsartan drug recalls. We’ll continue to post regular updates on the investigation to keep the public informed about affected products: https://t.co/HZb3YT0060

Patients who have received drug products produced by Pharm D and have concerns should contact their health care professional. #FDA will continue to work to mitigate risk and assure the safety of compounded drug produced by outsourcing facilities.

RT @FDA_Drug_Info: Join FDA for a public meeting Nov 27 to provide input on the underlying causes of #drugshortages & make recommendations for actions to prevent or reduce drug shortages. https://t.co/jCNYI

Now Showing: When Good Thanksgiving Leftovers Go Bad! Don’t want a starring role in this production? Check out this chart to find out how long every type of food stays good in the fridge or freezer. https://t.co/bkL7j25qmA https://t.co/ESFtU8cUSM

ALERT: Patients and healthcare professionals should check their medical supplies for compounded sterile drug products from Pharm D Solutions due to lack of sterility assurance. These products could put patients at risk. https://t.co/RpjCiZsC3u

Setting out a buffet for Thanksgiving? Check out how to serve it up safe: https://t.co/TTMjXHv0Op https://t.co/MlIucGRMyA

New efforts to strengthen device safety registry networks containing patient data will help us answer crucial questions especially for devices affecting women’s health to better treat fibroids, pelvic floor disorders and other conditions. https://t.co/9AurKaim6v https://t.co/rt0NFxRR2e

NEW REPORT: Strong actions taken by @FDADeviceInfo to increase inspections of foreign medical device firms by 243% over past decade; increased oversight led to improved compliance, improved device quality; more details in newly issued enforcement report https://t.co/3oWAUrvygW https://t.co/Sio0vPR1ex

RT @FDASpox: FDA is alerting patients and health care professionals to a voluntary recall of certain lots of valsartan-containing products from Mylan, due to an NDEA impurity. See the list of valsartan pr

RT @FDAOncology: New to cancer patient advocacy wondering how FDA works? Join us Tuesday, Nov 27, for #FDAOncology's 2nd annual workshop, Partners in Progress #OCEPIP18 in person at FDA or online: https://t.c

#FDA employs targeted, risk-based approach to address specific device concerns. We sent six warning letters to makers of automated external defibrillators and worked w/firms to address problems; now 70% drop in annual recalls and 27% drop in adverse events https://t.co/3oWAUrvygW https://t.co/4yeARQIz1h